Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use
Lara C. Czabaniuk, Thousand Oaks, CA (US); Timothy Hopper, Thousand Oaks, CA (US); Jonathan B. Houze, Cambridge, MA (US); Gwenaella Rescourio, Thousand Oaks, CA (US); Vincent Santora, Thousand Oaks, CA (US); Haoxuan Wang, Thousand Oaks, CA (US); Ryan D. White, Thousand Oaks, CA (US); Alice R. Wong, Thousand Oaks, CA (US); and Yongwei Wu, Thousand Oaks, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US); and Vigil Neuroscience, Inc., Cambridge, MA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US); and Vigil Neuroscience, Inc., Cambridge, MA (US)
Filed on Nov. 30, 2022, as Appl. No. 18/72,497.
Application 18/072,497 is a continuation of application No. 17/923,160, previously published as PCT/US2021/030719, filed on May 4, 2021.
Claims priority of provisional application 63/019,768, filed on May 4, 2020.
Prior Publication US 2023/0144581 A1, May 11, 2023